Key points A 47-year-old French-speaking woman of African descent presented to the emergency department with a 1-week history of severe foot pain and difficulty walking. For the preceding 2 months she ...

It is being studied in phase 3 trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Fate Therapeutics, Inc.’s FATE share price has surged by 10.29%, which has investors questioning if this is right time to ...

Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 95.90%, which has investors questioning if this is right time to sell.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

China: A recent study highlights the potential of ultrasonic viscoelastic imaging as a noninvasive tool for evaluating ...